GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aileron Therapeutics Inc (NAS:ALRN) » Definitions » Price-to-Owner-Earnings

Aileron Therapeutics (Aileron Therapeutics) Price-to-Owner-Earnings : (As of May. 02, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Aileron Therapeutics Price-to-Owner-Earnings?

As of today (2024-05-02), Aileron Therapeutics's share price is $4.17. Aileron Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Aileron Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


ALRN's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.25
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-02), Aileron Therapeutics's share price is $4.17. Aileron Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.41. Therefore, Aileron Therapeutics's PE Ratio for today is At Loss.

As of today (2024-05-02), Aileron Therapeutics's share price is $4.17. Aileron Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-3.25. Therefore, Aileron Therapeutics's PE Ratio without NRI for today is At Loss.


Aileron Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Aileron Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aileron Therapeutics Price-to-Owner-Earnings Chart

Aileron Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only - - - - -

Aileron Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aileron Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Aileron Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aileron Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aileron Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Aileron Therapeutics's Price-to-Owner-Earnings falls into.



Aileron Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Aileron Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=4.17/-4.44
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aileron Therapeutics  (NAS:ALRN) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Aileron Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Aileron Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Aileron Therapeutics (Aileron Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
285 Summer Street, Unit 101, Boston, MA, USA, 02210
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects.
Executives
James Brian Windsor officer: See Remarks 2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746
William Fairey director C/O CHEMOCENTRYX, INC., 850 MAUDE AVE., MOUNTAIN VIEW CA 94043
Alan A Musso director FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Susan L. Drexler officer: See Remarks 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Muneer A Satter 10 percent owner C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Reinhard J. Ambros director C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139
Von Rickenbach Josef H director C/O PAREXEL INTERNATIONAL CORPORATION, WALTHAM MA 02451-1163
Jeffrey Allen Bailey director BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Vojo Vukovic officer: SVP, Chief Medical Officer C/O SYNTA PHARMACEUTICALS CORP., 45 HARTWELL AVENUE, LEXINGTON MA 02421
Kathryn Gregory officer: SVP, Chief Business Officer 305 THAYER POND ROAD, WILTON CT 06897
William Mckee director
Nolan Howard Sigal director 941 BERRY AVENUE, LOS ALTOS CA 94024
Novartis Bioventures Ltd 10 percent owner C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
Rick Wanstall officer: VP, Finance and Operations C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472
Longenecker John P Phd officer: President and CEO 10445 PACIFIC CENTER CT, SAN DIEGO CA 92121

Aileron Therapeutics (Aileron Therapeutics) Headlines

From GuruFocus

Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split

By Value_Insider Value_Insider 11-10-2022

Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022

By GuruFocusNews GuruFocusNews 07-02-2022